Where Sipuleucel-T Fits in the Treatment of mCRPC

Paul R. Sieber, MD, and Nicholas Aksu
Published: Friday, Aug 09, 2019
Paul R. Sieber, MD, FACS

Paul R. Sieber, MD, FACS
Sipuleucel-T (Provenge) received an FDA approval in 2010 and a subsequent CMS coverage decision in 2011. At Lancaster Urology in Pennsylvania, we began infusing sipuleucel-T in 2011, and at the 7-year mark, we conducted a review to evaluate these first years of therapy. We had complete information on 94 patients.

illustrates, most of these men were alive at the time of this review. The median age was 74. Roughly 70% of men with a PSA <22.1 were alive at the time of this review.

Table 1. Survivorship Following Treatment With Sipuleucel-T

Table 1. Survivorship Following Treatment With Sipuleucel-T
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x